119 related articles for article (PubMed ID: 31554952)
1. Repurposing drugs: Ca
Baig AM; Katyara P; Khaleeq A; Nazim F
Eye (Lond); 2019 Nov; 33(11):1823-1825. PubMed ID: 31554952
[No Abstract] [Full Text] [Related]
2. Evidence of human-like Ca
Baig AM; Rana Z; Waliani N; Karim S; Rajabali M
Chem Biol Drug Des; 2019 Mar; 93(3):351-363. PubMed ID: 30362253
[TBL] [Abstract][Full Text] [Related]
3. Antibiotic Effects of Loperamide: Homology of Human Targets of Loperamide with Targets in Acanthamoeba spp.
Baig AM; Rana Z; Mannan M; Tariq S; Ahmad HR
Recent Pat Antiinfect Drug Discov; 2017; 12(1):44-60. PubMed ID: 28506204
[TBL] [Abstract][Full Text] [Related]
4. Number of Bacteria and Time of Coincubation With Bacteria Required for the Development of Acanthamoeba Keratitis.
Nakagawa H; Hattori T; Koike N; Ehara T; Narimatsu A; Kumakura S; Matsumoto T; Goto H
Cornea; 2017 Mar; 36(3):353-357. PubMed ID: 28079686
[TBL] [Abstract][Full Text] [Related]
5. N-chlorotaurine Inactivates Acanthamoeba and Candida albicans in the Porcine Ex Vivo Corneal Infection Model.
Teuchner B; Wibmer ID; Schaumann P; Seifarth C; Walochnik J; Nagl M
Cornea; 2019 Aug; 38(8):1011-1016. PubMed ID: 30932935
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of Topical Miltefosine in Patients with Acanthamoeba Keratitis: A Pilot Study.
Bagga B; Joseph J; Garg P; Chandran K; Jayabhasker P; Manjulatha K; Sharma S
Ophthalmology; 2019 May; 126(5):768-770. PubMed ID: 30572075
[No Abstract] [Full Text] [Related]
7. Potential Value of Cellulose Synthesis Inhibitors Combined With PHMB in the Treatment of Acanthamoeba Keratitis.
Moon EK; Hong Y; Chung DI; Goo YK; Kong HH
Cornea; 2015 Dec; 34(12):1593-8. PubMed ID: 26426333
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic agents and biocides for ocular infections by free-living amoebae of Acanthamoeba genus.
Carrijo-Carvalho LC; Sant'ana VP; Foronda AS; de Freitas D; de Souza Carvalho FR
Surv Ophthalmol; 2017; 62(2):203-218. PubMed ID: 27836717
[TBL] [Abstract][Full Text] [Related]
9. In vitro activity of isavuconazole against three species of Acanthamoeba.
Brunet K; Eestermans R; Rodier MH; Cateau E
J Fr Ophtalmol; 2020 Apr; 43(4):330-333. PubMed ID: 32151474
[TBL] [Abstract][Full Text] [Related]
10. Acanthamoeba castellanii: A new high-throughput method for drug screening in vitro.
Ortega-Rivas A; Padrón JM; Valladares B; Elsheikha HM
Acta Trop; 2016 Dec; 164():95-99. PubMed ID: 27609636
[TBL] [Abstract][Full Text] [Related]
11. Metformin-coated silver nanoparticles exhibit anti-acanthamoebic activities against both trophozoite and cyst stages.
Anwar A; Soomaroo A; Anwar A; Siddiqui R; Khan NA
Exp Parasitol; 2020 Aug; 215():107915. PubMed ID: 32461112
[TBL] [Abstract][Full Text] [Related]
12. Cellulose biosynthesis pathway is a potential target in the improved treatment of Acanthamoeba keratitis.
Dudley R; Alsam S; Khan NA
Appl Microbiol Biotechnol; 2007 May; 75(1):133-40. PubMed ID: 17225099
[TBL] [Abstract][Full Text] [Related]
13. Effect of Riboflavin/Rose Bengal-Mediated PACK-CXL on Acanthamoeba Trophozoites and Cysts in Vitro.
Atalay HT; Dogruman-Al F; Sarzhanov F; Özmen MC; Tefon AB; Arıbaş YK; Bilgihan K
Curr Eye Res; 2018 Nov; 43(11):1322-1325. PubMed ID: 30021467
[TBL] [Abstract][Full Text] [Related]
14. Differential expression of Acanthamoeba castellanii proteins during amoebic keratitis in rats.
Carvalho-Silva AC; Coelho CH; Cirelli C; Crepaldi F; Rodrigues-Chagas IA; Furst C; Pimenta DC; Toledo JS; Fernandes AP; Costa AO
Exp Parasitol; 2021 Feb; 221():108060. PubMed ID: 33338467
[TBL] [Abstract][Full Text] [Related]
15. Torn from the headlines: role of public awareness and bench- to-bedside research in prevention and treatment of Acanthamoeba keratitis.
Baig AM
Eye (Lond); 2019 May; 33(5):698-701. PubMed ID: 30552420
[No Abstract] [Full Text] [Related]
16. Bioinformatic Insights on Target Receptors of Amiodarone in Human and Acanthamoeba castellanii.
Baig AM; Rana Z; Tariq SS; Ahmad HR
Infect Disord Drug Targets; 2017; 17(3):160-177. PubMed ID: 28637420
[TBL] [Abstract][Full Text] [Related]
17. Differential effects of alpha-helical and beta-hairpin antimicrobial peptides against Acanthamoeba castellanii.
Sacramento RS; Martins RM; Miranda A; Dobroff AS; Daffre S; Foronda AS; De Freitas D; Schenkman S
Parasitology; 2009 Jul; 136(8):813-21. PubMed ID: 19490729
[TBL] [Abstract][Full Text] [Related]
18. Synergy Testing of Antiamoebic Agents for Acanthamoeba: Antagonistic Effect of Voriconazole.
Talbott M; Cevallos V; Chen MC; Chin SA; Lalitha P; Seitzman GD; Lietman TM; Keenan JD
Cornea; 2019 Oct; 38(10):1309-1313. PubMed ID: 31306283
[TBL] [Abstract][Full Text] [Related]
19. The Acanthamoeba-Fungal Keratitis Study.
Raghavan A; Baidwal S; Venkatapathy N; Rammohan R
Am J Ophthalmol; 2019 May; 201():31-36. PubMed ID: 30721687
[TBL] [Abstract][Full Text] [Related]
20. Neuroleptic Drug Targets a Brain-Eating Amoeba: Effects of Promethazine on Neurotropic Acanthamoeba castellanii.
Baig AM; Katyara P; Rajabali MN; Khaleeq A; Nazim F; Lalani S
ACS Chem Neurosci; 2019 Jun; 10(6):2868-2876. PubMed ID: 30977998
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
